Patents by Inventor Magnus Brisander

Magnus Brisander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Injectable Suspensions
    Publication number: 20250041206
    Abstract: The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
    Type: Application
    Filed: June 14, 2024
    Publication date: February 6, 2025
    Applicant: ASARINA PHARMA AB
    Inventors: Magnus Brisander, Karol Horvath, Björn Norrlind
  • Pharmaceutical compositions
    Patent number: 12144804
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: July 22, 2024
    Date of Patent: November 19, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 12076314
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: September 3, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 11963951
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: April 23, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Fast dissolving pharmaceutical compositions
    Patent number: 11529351
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 20, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Thomas Meijer, Victor Söderberg
  • Pharmaceutical compositions
    Patent number: 11517562
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: December 6, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 11426391
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: August 30, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 11376243
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: July 5, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 11241419
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: February 8, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Injectable Suspensions
    Publication number: 20210100736
    Abstract: The present invention relates to aseptic suspensions, physically stable and injectable through a 25 G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 8, 2021
    Applicant: ASARINA PHARMA AB
    Inventors: Magnus Brisander, Karol Horvath, Björn Norrlind
  • Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
    Patent number: 10933014
    Abstract: The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 2, 2021
    Assignee: ASARINA PHARMA AB
    Inventors: Magnus Brisander, Karol Horvath, Björn Norrlind
  • Pharmaceutical compositions
    Patent number: 10772877
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: September 15, 2020
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 10561644
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 18, 2020
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 10561643
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 18, 2020
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 10561645
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 18, 2020
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 10555937
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 11, 2020
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Injectable Suspensions
    Publication number: 20190350838
    Abstract: The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 21, 2019
    Applicant: ASARINA PHARMA AB
    Inventors: Magnus Brisander, Karol Horvath, Björn Norrlind
  • Pharmaceutical compositions
    Patent number: 10314829
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 11, 2019
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Pharmaceutical compositions
    Patent number: 10314830
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: June 11, 2019
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20190060294
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 28, 2019
    Applicant: Xspray Microparticles AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand